BRISTOL, Tenn. — USAntibiotics, the sole U.S. manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, announced today the appointment of Mark Tengler as the company’s new senior vice president of manufacturing technologies. With over three decades of experience in the pharmaceutical industry, Tengler will oversee the manufacturing operations at USAntibiotics’ 394,000-square-foot facility. His responsibilities will include management of antibiotic processing and packaging, plastics processing, engineering, maintenance, building services, and warehouse operations.
Patrick Cashman, president of USAntibiotics, expressed enthusiasm about Tengler’s appointment, stating, “We are delighted to welcome Mark to the USAntibiotics leadership team. His extensive experience in pharmaceutical manufacturing, regulatory compliance, and process innovation perfectly aligns with our commitment to operational excellence. As we continue to grow and strengthen the nation’s supply of life-saving antibiotics, Mark’s leadership will be critical to advancing our mission and positively impacting millions of Americans.”
Tengler’s career has been marked by significant achievements in driving innovation and optimizing complex workflows within the pharmaceutical sector. Known for his ability to lead cross-functional teams and develop integrated operational strategies, he has a history of fostering sustained growth in competitive markets.
Before joining USAntibiotics, Tengler held several executive leadership roles at companies such as Spectrix Therapeutics, LLC, and PharmaFab, LLC. Notably, he played a pivotal role in transitioning PharmaFab into Neos Therapeutics, Inc. in 2006, where he served as founder, president, and chief technology officer. Under his leadership, Neos Therapeutics successfully made its debut on the Nasdaq.
Tengler’s appointment comes as USAntibiotics continues to expand its operations and strengthen the domestic supply of critical antibiotics, ensuring the continued availability of medications such as Amoxil® and Augmentin® for patients across the United States.
